Moxifloxacin
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Moxifloxacin: From Bacterial Infections to Hyperamylasemia
One-Sentence Summary
Moxifloxacin is a fluoroquinolone antibacterial. The registration data provided does not state its approved indication text. The TxGNN model predicts it may be effective for hyperamylasemia, but there are currently 0 clinical trials and 0 publications supporting this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the registration data; moxifloxacin is a fluoroquinolone antibacterial (bacterial infections) |
| Predicted New Indication | Hyperamylasemia |
| TxGNN Prediction Score | 99.98% |
| Evidence Level | L5 |
| South Africa Market Status | Marketed |
| Number of SAHPRA Registrations | 2 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, moxifloxacin is a fluoroquinolone antibacterial that acts on bacterial DNA gyrase and topoisomerase IV. Its use is in bacterial infections.
No mechanistic rationale links moxifloxacin to hyperamylasemia (elevated serum amylase). The prediction comes from a very high knowledge-graph score alone. It is not supported by trials, literature or a plausible pharmacological pathway. The score should be read as a model output that needs verification, not as evidence of benefit.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
South Africa Market Information
| Registration Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| Reg. No. 41/20.1.1/0777 | Numoxx | Tablet (oral) | Not listed in the data provided |
| Reg. No. 49/20.1.1/0675 | Moxifloxacin 400Mg/250Ml Fresenius | Infusion (injectable) | Not listed in the data provided |
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has a very high model score but no clinical trials, no literature and no plausible mechanism. It is L5 evidence only. Safety and mechanism data are also missing, so there is no basis to advance it.
To proceed, the following is needed:
- The SAHPRA package insert (warnings, contraindications, approved indications), which blocks any safety screening
- Mechanism of action data (for example from DrugBank) to test for any link to hyperamylasemia
- Any human or preclinical evidence for moxifloxacin in hyperamylasemia
- A route compatibility assessment (oral tablet and intravenous infusion are registered)
Note on other predictions for this drug: Among the lower-ranked predictions, bubonic plague (rank 10) has the strongest support. It rests on 5 preclinical or in vitro studies showing activity against Yersinia pestis and is classed L4 (Research Question). It is closer to an extension of the antibacterial spectrum than to true repurposing, and it has no human trials. It could be evaluated separately, after the safety data gap is closed.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.